🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Really interesting work on the biological heterogeneity of liver metastases in colon cancer. Gets to the broader concept of predicting prognosis based on clinical & biomarker profiles of pts who all fit under the heading of metastatic cancer but show different patterns.

Thrilled to share our recent work published in JAMA Oncology validating the molecular subtypes of oligometastatic CRC in the phase 3 randomized New-EPOC trial! UChicagoCancerCenter The University of Chicago UChicago Medicine University of Chicago Radiation Oncology Ludwig Cancer jamanetwork.com/journals/jamao…

Molecular subtypes of colorectal liver mets & an integrated clinical-molecular risk stratification are prognostic in this independent validation within New EPOC phase III randomized trial, offering a framework to stage metastatic disease ja.ma/3pTecRx #CRCSM #GICSM

📣Just published: Sean Pitroda, MD (Sean Pitroda, M.D.) and colleagues published a new study in JAMA Oncology validating the #biomarkers for predicting outcomes for #colorectalcancer patients with liver metastasis. UChicagoCancerCenter UChicago Medicine University of Chicago Radiation Oncology ow.ly/aJRN50Pho77

Great paper - congrats! Biomarkers needed to risk stratify in liver oligometastatic CRC & select for patients who might benefit most from SBRT. Furthermore, there is also data on presence of liver mets being immunosuppressive & poorly responsive to IO - but that adding SBRT

🎙️ Molecular subtypes of #colorectal liver metastases are prognostic ‼️OncoAlert JAMA Oncology 📌Retro analysis Ph 3 New EPOC trial 240 👥w/ liver metastases - 🔍 Discovery (93 👥) & Validation cohort (147 👥) - 💉 Interventions: RNA sequencing & microRNA profiling 🥇🎯:Validate

In our #AskAScientist series on promising areas of cancer research for those starting their scientific careers, Ludwig UChicago Medicine’s Ralph Weichselbaum highlights bioinformatic analysis as a key skill for future researchers.

Very excited to have aspiring Radiation Oncologists Montse Quintana MS4 (UToledo Medicine) and @lfspurr MS4 (UChicago Pritzker School of Medicine) rotate with us at UCMC #RadOnc. #GME #UME #MedEd

Our data presented at #ESMO23 suggests ctHPVDNA dynamics during neoadjuvant chemotherapy in context of response-adaptive de-escalation may be an early indicator of treatment effectiveness, along with as a surveillance strategy to detect and monitor recurrent disease.

Last night we had a celebration of Dr Gooi and his service to our section! He’ll be heading to Malaysia 🇲🇾 in December for his next chapter and we wish him all the best! He’ll be sorely missed as a dedicated clinician and educator #ENT #IamOto #MedTwitter #HNOncology

How can radiation cause immunosuppressive changes to the TME and promote a "badscopal" effect? Happy to contribute to this review led by Liangliang Wang discussing some possible mechanisms! authors.elsevier.com/c/1iDg2_yeTfNc… Ralph Weichselbaum Sean Pitroda, M.D. UChicagoCancerCenter University of Chicago Radiation Oncology

We could not be more proud that Yasmin Hasan has been named UChicago Program Director of the Year! #GME #MedEd #RadOnc #Residency #Match UChicago GME

Our review titled: SBRT for Liver Tumors: What the Interventional Radiologist Needs to Know, is out now! Many thanks to my talented colleagues Rohan Katipally, Michael Gutman, and Dr. Koshy. Link: thieme-connect.com/products/ejour…

Happy #matchday2024! We are thrilled to introduce our Class of 2029: Farris Jaamour, Mira Patel, and Montserrat Quintana! #RadOnc #GME UChicago Medicine #match2024

UChicago Medicine We also want to give a shout out to the residents from the class of 2028 who will be joining us this summer: Abed Rahman Kawakibi, Sophia Kim-Wang, and Ryan Zitter! #match2024 #RadOnc #GME #matchday2024

Could we hold off on checkpoint inhibitors in patients with low-volume metastatic disease and treat with local therapy instead? Our editorial exploring this idea: ascopubs.org/doi/10.1200/JC… (thanks to Ralph Weichselbaum Muzamil Arshad, MD/PhD Rohan Katipally Sean Pitroda, M.D.)

Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease: ascopubs.org/doi/10.1200/JC… Connor Lynch Muzamil Arshad, MD/PhD Rohan Katipally Ralph Weichselbaum UChicagoCancerCenter

🧐Our DEPEND trial is out! Neoadjuvant nivo/chemo followed by response-stratified CRT in HPV-negative stage IVa/b HNSCC. UChicagoCancerCenter University of Chicago Hematology/Oncology Aditya Juloori Pearson Lab Nishant Agrawal Evgeny Izumchenko Everett Vokes jamanetwork.com/journals/jamao…

Check out the latest from UChicagoCancerCenter HN Group - the DEPEND trial. 1) There is strong interest in determining how to incorporate immunotherapy into non-operative management for LA-HNSCC to improve outcomes for high risk HPV-negative patients.